Aernoud Fiolet

179 The efficacy and safety of low-dose colchicine in patients with coronary disease Table 1: Key features of included trials Trial Acronym Author Year Trial size Key inclusion criteria Key exclusion criteria Active treatment Comparator Multi- centre Open label run-in Follow-up (median, months) LoDoCo2 Nidorf 2020 5,522 Chronic coronary disease, clinically stable >6 months Heart failure (NYHA III/IV); renal failure (eGFR < 50 ml/min/1.73m2); severe valvular heart disease Colchicine 0.5mg once daily Placebo Yes Yes 29 COPS Tong 2020 795 Acute coronary syndrome with presence of coronary disease Requiring bypass surgery; severe liver impairment; severe renal impairment (eGFR < 30 ml/min/1.73m2) Colchicine 0.5mg twice daily for one month, followed by 0.5mg once daily Placebo Yes No 12 COLCOT Tardif 2019 4,745 Post myocardial infarction Heart failure (LVEF <35%); renal impairment (creatinine level >2x upper limit of normal); bypass surgery <3 years or planned Colchicine 0.5mg once daily Placebo Yes No 23 NA Deftereos 2013 222 Diabetes and undergoing percutaneous coronary revascularisation Acute myocardial infarction; renal impairment (eGFR < 20 ml/ min/1.73m2) ; liver failure Colchicine 0.5mg twice daily Placebo No No 6 LoDoCo Nidorf 2013 532 Chronic coronary disease, clinically stable >6 months Bypass surgery <10 years, major competing comorbidities Colchicine 0.5mg once daily No colchicine No No 36 Key features of included trials. eGFR=estimated glomerular filtration rate. LVEF=left ventricular ejection fraction. NA=not available. NYHA=New York Heart Association.